Prophylactic oral vaccination for SIV and SHIV infections and AIDS prevention

点击翻译按钮获取中文摘要

SUMMARY This proposal is designed to extend our previous studies where we achieved significant systemic and mucosal cellular responses after oral cavity and intestinal immunizations with a SIV DNA-rMVA approach. These immunizations had two important impacts on SIV exposure and infection: 1. the intestinal immunization provided significant protection from infection but no protection from disease progression; 2. the oral cavity immunization provided significant protection from disease with no AIDS development observed during the post-challenge follow up and with more than 50% of the animals controlling virus replication to undetectable blood levels after experiencing a peak of viremia, and apparently clearing the infection, as no rebound was observed after CD8+ T-cell depletion. Here we propose to investigate in Cynomolgus macaques anti-SIV and SHIV oral immunization approaches aimed at stimulating cellular immune responses, previously achieved via oral immunization, and persistent anti-Env IgG and IgA titers, previously sporadic or missing, systemically and at mucosal sites where HIV exposure occurs in humans. The goal sof the proposal are the following: I. To evaluate how oral immunization regimens composed of 1. pSIVvaxE543 DNA, boosted with gp140(smE543) Env and rMVA, 2. pSIVvaxE543 DNA + SIVgag239 and SIVenvsmE543 recombinant OPVs (collectively called SIV-OPV), and 3. SIV-OPV alone compare in their stimulation of cell mediated and humoral immunity systemically and at mucosal sites where HIV transmission occurs in humans, and whether they provide protection from heterologous SIVmac251 infection and disease in Cynomolgus macaques (CM). II. To evaluate stimulation of systemic and mucosal cell-mediated immunity and humoral immunity by three regimes that include SHIVBG505 DNA + SIVgag239-OPV and HIV Env-OPV, where Env in this last component is linear HIVBG505 gp140 in Group 1, a SOSIP-gp140 BG505 in Group 2, and a V1-V2 BG505 scaffold in Group 3, and whether these responses provide protection from heterologous SHIVAD8 infection and disease in CM; III. To evaluate the extent of anti-HIV Env antibody affinity maturation observed with repeated SHIV-OPV immunization. During these experiments we will evaluate mechanistic characteristics of the anti-SIV or SHIV immune response and correlates of protection from infection and disease, with focus on the analysis of intestinal mucosa responses and viral loads, viral reservoirs, and possibly eradication post infection.